# HC Wainwright

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/hc-wainwright-company
Canonical HTML page: https://getyourbrief.com/entity/hc-wainwright-company

## Timeline

- **2026-06-30**: Schikan sells 30,712 shares — Schikan sold an additional 30,712 shares at $35.49, totaling $1,089,969.
- **2026-06-29**: Schikan sells 6,888 shares — Director Johannes Gerardus Chri Schikan sold 6,888 shares at $35.05, totaling $241,424.
- **2026-06-16**: HC Wainwright reiterates buy rating — HC Wainwright reaffirmed its buy rating on Pharvaris shares.
- **2026-05-13**: UBS sets $74 price target — UBS Group issued a research note with a $74 price objective on Pharvaris.
- **2026-05-12**: Q1 earnings beat — Pharvaris reported Q1 EPS of -$0.70, beating the consensus estimate of -$0.82.
- **2026-04-21**: Weiss Ratings issues sell (d-) rating — Weiss Ratings reaffirmed a sell rating on Pharvaris shares, citing financial risks.
- **2026-04-07**: Wedbush raises price target to $42 — Wedbush lifted its price target on Pharvaris from $41 to $42 with an outperform rating.

## Recent coverage (12 stories, network-wide)

### Entera Bio Down 0.6% as $9.00 Analyst Target Highlights Split
2026-08-12 16:26:13 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Shares of Entera Bio slipped 0.6% to $1.54 on 78% below-average volume, but analysts remain deeply split: HC Wainwright reiterates buy while Weiss Ratings maintains a sell. The $9.00 consensus target implies roughly 484% upside for the $75.91M microcap biotech.
Full story: https://getbiobrief.com/story/entera-bio-down-06-analyst-target-9

### PVLA Drops 12.4% on Thin Volume: Biotech Risk or 45% Upside Play?
2026-08-12 12:09:27 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Palvella Therapeutics stock sank 12.4% Monday with no news, highlighting biotech liquidity risk. Analyst consensus target of $199.53 implies 45% upside, but earnings miss and two sell ratings complicate the picture for biotech investors.
Full story: https://getbiobrief.com/story/pvla-shares-down-12-4-biotech-analysis

### HALO stock hits $103 as FY2026 EPS guidance of $8.65-$9.00 overshoots consensus by $0.63
2026-08-12 02:50:02 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Halozyme Therapeutics posted a massive Q2 beat and raised FY2026 EPS guidance to $8.65-$9.00, well above the $8.02 consensus, triggering a two-day stock surge past $103. With a forward P/E near 11.5x and a PEG ratio of 0.36, the market is repricing the stock after realizing the royalty growth was underestimated.
Full story: https://getfinancebrief.com/story/halozyme-fy2026-earnings-guidance-beat-stock-surge

### Halozyme's ENHANZE drives 47.7% revenue surge and FY26 EPS guidance 8% above Street
2026-08-12 02:48:54 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Halozyme's Q2 2026 earnings showcased accelerating adoption of its ENHANZE drug delivery technology, with royalties from subcutaneous biologics like DARZALEX FASPRO pushing revenue up 47.7% YoY. The company issued FY2026 EPS guidance of $8.65-$9.00, handily beating consensus, signaling sustained growth from its partnered pipeline.
Full story: https://getbiobrief.com/story/halozyme-enhanze-partner-royalties-q2-2026-guidance

### TLPH Upgraded: Can $3 Target Close the 113% Gap for Talphera?
2026-08-11 12:30:02 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen’s hold upgrade caps a series of mixed analyst actions on Talphera, whose stock trades at $1.41 despite a $3.00 average target. Institutional positioning and a technical breakout suggest the market may be repricing a depressed small-cap. For investors, the gap represents both a unique opportunity and a cautionary tale of biotech volatility.
Full story: https://getfinancebrief.com/story/tlph-upgraded-113-percent-gap-finance

### TLPH Upgrade: 113% Upside to $3 Target Sparks Biotech Interest
2026-08-11 12:29:49 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Analyst action pushes Talphera into the spotlight as a deeply undervalued biotech, with a $3.00 average target offering over 100% upside. Recent earnings beat and institutional buying add to the narrative. Two buy initiations from specialized firms highlight confidence in the pain management pipeline.
Full story: https://getbiobrief.com/story/talphera-upgrade-biotech-113-upside-target

### SGP Hits $17.56 Low: 156% Upside to $45 Analyst Target
2026-08-10 05:23:16 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Spyglass Pharma's stock plunges to a new 52-week low of $17.56 despite a consensus 'Moderate Buy' rating and an average analyst target of $45. For biotech investors, the 156% upside potential must be weighed against a recent earnings miss and a downgrade to sell, raising questions about near-term pipeline catalysts.
Full story: https://getbiobrief.com/story/spyglass-pharma-52-week-low-156-percent-upside-bio

### Agenus Upgraded to Buy After 189% Surge Off 12M Low: Analysts Eye $30 Target
2026-08-08 12:53:05 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen upgraded biotech Agenus to buy despite a massive Q1 earnings miss, as the stock surged 189% from its 52-week low. Mixed analyst views and a $30 HC Wainwright target highlight the speculative upside in immuno-oncology.
Full story: https://getbiobrief.com/story/agenus-upgraded-buy-189-percent-surge

### HC Wainwright Cuts Circle (CRCL) to $104, Still Sees 64% Upside
2026-08-07 01:20:20 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

HC Wainwright and Needham lowered price targets on Circle Internet Group but maintained Buy ratings as analysts remain split on the stablecoin issuer. The stock trades at $63.48, far below the consensus target of $100.06, highlighting both opportunity and risk.
Full story: https://getfinancebrief.com/story/circle-crcl-price-target-cut-finance

### USDC Issuer Circle (CRCL) Sees Targets Slashed, Yet 100% Upside Possible
2026-08-07 01:20:09 · Sector: crypto · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Two investment banks cut their price targets on Circle Internet Group, the firm behind the USDC stablecoin, citing near-term headwinds—but both maintained Buy ratings with triple-digit upside potential. The stock’s deep pullback from its $189 high reflects broader crypto market caution.
Full story: https://getcryptobrief.com/story/circle-usdc-price-target-crypto

### $1.33M Insider Sale at Pharvaris: What It Means for HAE Drug Catalysts
2026-07-11 21:42:38 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Director Johannes Schikan sold $1.33 million in Pharvaris stock just as the company approaches critical Phase 3 readouts for its oral HAE therapy. With analysts split and institutions buying, the insider move adds a wrinkle to the risk-reward calculus ahead of binary clinical data.
Full story: https://getbiobrief.com/story/pharvaris-insider-sale-1.33m-hae-catalysts

### REGENXBIO CMO Sells $688K Shares After Q1 Miss, Yet Analysts See 99% Upside
2026-07-06 01:38:05 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 3

REGENXBIO Chief Medical Officer Steve Pakola offloaded 56,333 shares for $688,756 following a disastrous Q1 miss, but analysts maintain price targets implying up to 99% upside. The insider sales add tension to a gene therapy story already defined by high risk and potential reward.
Full story: https://getbiobrief.com/story/regenxbio-cmo-sells-688k-after-q1-miss-analyst-upside

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.